[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100141390":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":41,"centralContacts":30,"locations":44,"responsibleParty":56,"collaborators":30,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":30,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":30,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":30,"overallStatus":77,"whyStopped":30,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":30,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Boehringer Ingelheim","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"BI 10773 25 mg","EXPERIMENTAL","1 tablet 25 mg BI 10773 qd for 5 days",[13],"Drug: BI 10773 25 mg",{"label":15,"type":10,"description":16,"interventionNames":17},"BI 10773 25 mg + Warfarin 25 mg","1 tablet 25 mg BI 10773 qd for 7 days plus 5 tablets 5 mg warfarin single dose",[13,18],"Drug: Warfarin 25 mg",{"label":20,"type":21,"description":22,"interventionNames":23},"Warfarin 25 mg","ACTIVE_COMPARATOR","5 tablets 5 mg warfarin single dose",[24],"Drug: Warfarin",[26,31,34,37],{"type":27,"name":9,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","25 mg BI 10773 qd for 5 days",[15],null,{"type":27,"name":20,"description":32,"armGroupLabels":33,"otherNames":30},"25 mg Warfarin single dose",[15],{"type":27,"name":9,"description":35,"armGroupLabels":36,"otherNames":30},"25 mg BI 10773 qd for 12 days",[9],{"type":27,"name":38,"description":39,"armGroupLabels":40,"otherNames":30},"Warfarin","25 mg warfarin single dose with and without 50 mg BI 10773",[20],[42],{"name":5,"affiliation":5,"role":43},"STUDY_CHAIR",[45],{"facility":46,"status":30,"city":47,"state":30,"zip":30,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":30},"1245.18.1 Boehringer Ingelheim Investigational Site","Biberach","Germany","DE",{"type":51,"coordinates":52},"Point",[53,54],8.03333,48.33333,{"lat":54,"lon":53},{"type":57,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100141390","phase-1-drug-drug-interaction-of-empagliflozin-bi-10773-and-warfarin-in-healthy-volunteers-100141390",true,"NCT01111331","Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers","Relative Bioavailability of Both BI 10773 and Warfarin and Pharmacodynamics of Warfarin After Co-administration Compared to Multiple Oral Doses of BI 10773 (25 mg Once Daily) and a Single Oral Dose of Warfarin (25 mg) Alone in Healthy Male Volunteers (an Open-label, Crossover, Clinical Phase I Study)","Inclusion criteria:\n\nHealthy male subjects","MALE","18 Years","55 Years",{"count":69,"type":70},18,"ACTUAL","INTERVENTIONAL",[73],"PHASE1","The objective of the current study is to investigate the bioavailability of BI 10773 and of warfarin after concomitant multiple oral administration of BI 10773 and a single oral dose of warfarin in comparison to BI 10773 and warfarin given alone, and to investigate the pharmacodynamics of a single oral dose of warfarin with and without concomitant multiple oral administration of BI 10773.",[76],"Healthy","COMPLETED","2014-06-25",{"date":80,"type":81},"2014-07-23","ESTIMATED",{"date":83,"type":30},"2010-05",{"name":5,"class":6},1]